CA3070252A1 - Binding proteins 1 - Google Patents

Binding proteins 1 Download PDF

Info

Publication number
CA3070252A1
CA3070252A1 CA3070252A CA3070252A CA3070252A1 CA 3070252 A1 CA3070252 A1 CA 3070252A1 CA 3070252 A CA3070252 A CA 3070252A CA 3070252 A CA3070252 A CA 3070252A CA 3070252 A1 CA3070252 A1 CA 3070252A1
Authority
CA
Canada
Prior art keywords
seq
sequence
binding protein
cancer
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3070252A
Other languages
English (en)
French (fr)
Inventor
James Campbell
Valentina DUBLJEVIC
James Hansen
Zahra RATTRAY
Jiangbing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucleus Therapeutics Pty Ltd
Yale University
Original Assignee
Nucleus Therapeutics Pty Ltd
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleus Therapeutics Pty Ltd, Yale University filed Critical Nucleus Therapeutics Pty Ltd
Publication of CA3070252A1 publication Critical patent/CA3070252A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3070252A 2017-07-17 2018-07-17 Binding proteins 1 Pending CA3070252A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762533546P 2017-07-17 2017-07-17
US62/533,546 2017-07-17
US201762596694P 2017-12-08 2017-12-08
US62/596,694 2017-12-08
PCT/US2018/042532 WO2019018426A1 (en) 2017-07-17 2018-07-17 BINDING PROTEINS 1

Publications (1)

Publication Number Publication Date
CA3070252A1 true CA3070252A1 (en) 2019-01-24

Family

ID=65015294

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3070252A Pending CA3070252A1 (en) 2017-07-17 2018-07-17 Binding proteins 1

Country Status (8)

Country Link
US (5) US11613590B2 (enExample)
EP (1) EP3655432A4 (enExample)
JP (2) JP7690285B2 (enExample)
CN (1) CN111094338A (enExample)
AU (1) AU2018302110B2 (enExample)
CA (1) CA3070252A1 (enExample)
IL (1) IL272064A (enExample)
WO (2) WO2019018426A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744840T3 (es) 2011-04-01 2020-02-26 Univ Yale Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CA3027960C (en) 2016-06-15 2022-06-14 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
SG11202101975RA (en) 2018-08-31 2021-03-30 Univ Yale Compositions and methods for enhancing donor oligonucleotide-based gene editing
US20210340279A1 (en) * 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
KR20220101073A (ko) 2019-08-30 2022-07-19 예일 유니버시티 핵산을 세포로 전달하기 위한 조성물 및 방법
JP2023544970A (ja) 2020-08-31 2023-10-26 イエール ユニバーシティ 細胞への核酸の送達のための組成物及び方法
CN117295753A (zh) 2020-12-04 2023-12-26 基那奥生物公司 用于将核酸递送到细胞的组合物和方法
JP2024508309A (ja) 2021-03-03 2024-02-26 イエール ユニバーシティ 骨格筋疾患を治療するための組成物及び方法
JP2024519169A (ja) * 2021-05-25 2024-05-08 トランスマブ・ピーティーワイ・リミテッド 改善された免疫グロブリンｉ
US20240226311A1 (en) * 2021-05-25 2024-07-11 Transmab Pty Ltd Improved immunoglobulin II
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
WO2023114887A2 (en) * 2021-12-15 2023-06-22 The Trustees Of Indiana University Cell targeting compositions and methods
WO2023168401A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for treating disease
EP4486386A1 (en) 2022-03-03 2025-01-08 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
US20230303719A1 (en) * 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
AU2023338626A1 (en) 2022-09-09 2025-03-20 Yale University Proteolysis targeting antibodies and methods of use thereof
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates
EP4655007A1 (en) 2023-01-23 2025-12-03 Yale University Antibody oligonucleotide conjugates
WO2024197302A1 (en) 2023-03-23 2024-09-26 Yale University Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping
WO2025049905A1 (en) 2023-09-01 2025-03-06 Gennao Bio, Inc. Dnase co-expression in host cells
WO2025090121A1 (en) * 2023-10-27 2025-05-01 Yale University Conjugate and methods of treatment
WO2025097000A1 (en) 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
CN121159711A (zh) * 2024-01-02 2025-12-19 河北神宇生物技术有限公司 一种提高adc药物疗效的重组蛋白及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
CA2907072A1 (en) 2012-03-16 2013-09-19 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of dmpk
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
JP6709733B2 (ja) * 2014-01-13 2020-06-17 バレリオン セラピューティクス， エルエルシー 内在化部分
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
WO2015192092A1 (en) 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
AU2015308894A1 (en) * 2014-08-27 2017-03-23 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
US20170291961A1 (en) * 2014-08-28 2017-10-12 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
US10383945B2 (en) * 2015-02-18 2019-08-20 The United States of America as Represented by the Department of Verterans Affairs Methods for DNA-dependent targeting of a cell permeant antibody

Also Published As

Publication number Publication date
US20230406960A1 (en) 2023-12-21
US20200216567A1 (en) 2020-07-09
IL272064A (en) 2020-03-31
WO2019018426A1 (en) 2019-01-24
CN111094338A (zh) 2020-05-01
AU2018302110B2 (en) 2024-11-21
AU2018302110A1 (en) 2020-02-06
JP2020527355A (ja) 2020-09-10
JP2023083385A (ja) 2023-06-15
US20250376540A1 (en) 2025-12-11
JP7690285B2 (ja) 2025-06-10
US11613590B2 (en) 2023-03-28
US20240052063A1 (en) 2024-02-15
WO2019018428A1 (en) 2019-01-24
EP3655432A1 (en) 2020-05-27
US20200216568A1 (en) 2020-07-09
EP3655432A4 (en) 2021-04-14
US12312417B2 (en) 2025-05-27

Similar Documents

Publication Publication Date Title
US12312417B2 (en) Binding proteins 1
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
TWI679022B (zh) 抗-ｐｔｋ７抗體-藥物結合物
US20210380680A1 (en) Anti-claudin antibodies and uses thereof
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
TW202136314A (zh) 抗ｃｃｒ８抗體及其用途
JP7366886B2 (ja) Ａｘｌ特異的抗体及びその使用
CN116133694A (zh) 抗her3抗体和抗her3抗体药物偶联物及其医药用途
KR101820029B1 (ko) 암의 예방 및/또는 치료에서 사용하기 위한 방사성 표지 항체 단편
TW201643195A (zh) 對細胞內致癌基因產物的單株抗原結合蛋白
CN106459211A (zh) 双功能抗体及其用途
JP7485368B2 (ja) 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
CN103025760A (zh) 人源化egfr抗体
WO2017196764A1 (en) Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
TW202200209A (zh) 用於優化之藥物接合之經修飾的結合多肽
CN114585647A (zh) 抗grp78抗体及其使用方法
US20240270851A1 (en) Cross species single domain antibodies targeting pd-l1 for treating solid tumors
Steiner Targeted delivery of cytotoxic agents: direct conjugation to antibodies and pretargeting approaches
TW202432185A (zh) 配體－細胞毒性藥物綴合物及其藥物用途
TW201711702A (zh) 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
TW202417054A (zh) 配體－細胞毒性藥物偶聯物及其藥物用途
TW202535960A (zh) 抗體及其藥物偶聯物和用途
TW202432186A (zh) 配體-細胞毒藥物綴合物及其醫藥用途
HK40089485A (zh) 抗cldn-18.2抗体药物偶联物及其用途
HK40064761B (zh) 抗cd228抗体和抗体-药物缀合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928